Find
News Releases
= add release to Briefcase
| All Releases | |||
|---|---|---|---|
 |
Johnson & Johnson Announces Executive Appointments: Sheri McCoy, Worldwide Chairman, Pharmaceuticals Group, and Alex Gorsky, Worldwide Chairman, Surgical Care Group Oct 9, 2008 |
6.8 KB |
|
|
NEW BRUNSWICK, N.J., Oct 09, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson today announced that Sheri McCoy, currently Worldwide Chairman, Surgical Care Group, has been appointed Worldwide Chairman, Pharmaceuticals Group, effective January 1, 2009. In this role, Ms. McCoy succeeds Christine Poon, who last month announced ... |
|||
|
McNeil Consumer Healthcare Supports Voluntary Initiatives To Help Encourage Safe, Effective Use Of Children's Cough And Cold Medicines Oct 7, 2008 |
26.9 KB |
|
|
Fort Washington, PA (October 7, 2008) - As part of the industry's continuing dialogue with the U.S. Food and Drug Administration (FDA), McNeil Consumer Healthcare, a division of McNeil-PPC, Inc., announced today new voluntary actions that will help further encourage safe and appropriate use of children's cough and cold medicines. ... |
|||
|
Johnson & Johnson to Host Analyst Meeting to Discuss Third-Quarter Financial Results and Review Pharmaceutical Business Oct 7, 2008 |
5.6 KB |
|
|
NEW BRUNSWICK, N.J., Oct 07, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson will host an analyst meeting at 8:30 a.m. (Eastern Time) on Tuesday, October 14, 2008, to discuss third-quarter financial results and review its Pharmaceutical business. The meeting will be hosted by Christine Poon, Vice Chairman, Board of Director... |
|||
|
U.S. District Court in Delaware Enters Final Judgment of Approximately $1.2 Billion to Cordis Corporation on Patents Infringed by Medtronic, Inc. and Boston Scientific Corporation Sep 30, 2008 |
5.7 KB |
|
|
MIAMI LAKES, Fla., Sept 30, 2008 /PRNewswire via COMTEX News Network/ -- The U.S. District Court in Delaware today entered final judgment including accrued interest, totaling approximately $1.2 billion, to Cordis Corporation against Medtronic, Inc. and Boston Scientific Corporation in cases involving the original Palmaz balloon expandable stent pat... |
|||
|
Findings from Landmark Study show Ustekinumab Demonstrated Superior Efficacy to Enbrel® (Etanercept) in Treatment of Moderate to Severe Plaque Psoriasis Sep 18, 2008 |
10.6 KB |
|
|
HORSHAM, PA, September 18, 2008 - New findings from a Phase 3 multicenter, randomized head-to-head study comparing ustekinumab and Enbrel® (etanercept) for the treatment of moderate to severe psoriasis showed ustekinumab superior to Enbrel according to primary and major secondary efficacy endpoints. The pr... |
|||
|
Preliminary Data from Experimental Study Demonstrate Increased Mortality in Stroke Patients Treated With Epoetin Alfa Sep 17, 2008 |
5.8 KB |
|
|
BRIDGEWATER, NJ -- (September 17, 2008) -- Ortho Biotech has become aware of preliminary data from an investigator-initiated experimental study of the effects of Epoetin alfa in patients with acute ischemic stroke. In this study, patients suffering acute ischemic stroke who were treated with Epoetin alfa within six hours of the onset of stroke s... |
|||
|
U.S. District Court in Delaware Reinstates Damage Awards to Cordis Corporation on Patents Infringed by Medtronic, Inc. and Boston Scientific Corporation Sep 15, 2008 |
6.0 KB |
|
|
MIAMI, Sept 15, 2008 /PRNewswire via COMTEX News Network/ -- The U.S. District Court in Delaware today granted Cordis Corporation's motion for final judgment against Boston Scientific Corporation and Medtronic, Inc. in their cases involving the original Palmaz balloon expandable stent patent. Cordis had asked U.S. District Court Judge Sue Robin... |
|||
|
Christine A. Poon Plans Retirement from Johnson & Johnson in Early 2009 Sep 12, 2008 |
6.5 KB |
|
|
NEW BRUNSWICK, N.J., Sept 12, 2008 /PRNewswire-FirstCall via COMTEX News Network/ -- Johnson & Johnson said today that Christine A. Poon, 56, Vice Chairman of the Board of Directors and Worldwide Chairman, Pharmaceuticals Group, has announced plans to retire on March 1, 2009, from the Company and the Board, after more than 23 years in the health ca... |
|||
|
Ortho Biotech Files sNDA for DOXIL® for the Treatment of Advanced Breast Cancer Sep 8, 2008 |
13.6 KB |
|
|
Bridgewater, NJ (September 8, 2008) - Ortho Biotech Products, L.P. today announced that the Company has submitted a supplemental new drug application (sNDA) to the U.S. Food and Drug Administration (FDA) for the combination of DOXIL® (doxorubicin HCl liposome injection) and Taxotere® (docetaxel)* for the treatment of women with advanced ... |
|||
|
VELCADE* for multiple myeloma receives front-line approval in Canada Sep 8, 2008 |
10.4 KB |
|
|
Toronto, Ontario (September 8, 2008) - VELCADE* (bortezomib) for Injection has received Health Canada approval for front-line (first) treatment of multiple myeloma, a fatal blood cancer. As part of combination therapy, VELCADE is indicated for the treatment of patients with previously untreated multiple myeloma who are unsuitable for stem cell t... |
|||
|
VELCADE® (bortezomib) Approved For Previously Untreated Multiple Myeloma Sep 8, 2008 |
10.1 KB |
|
|
High Wycombe, England (September 8, 2008) Janssen-Cilag / Ortho Biotech, the biopharmaceutical division of Janssen-Cilag, today announced the European Commission's approval of VELCADE in combination with melphalan and prednisone for the treatment of patients with previously untreated multiple myeloma (MM) who are not eligible for high-dose chemo... |
|||
|
Clinical Data Indicate that Percutaneous Coronary Intervention with the CYPHER(R) Sirolimus-eluting Coronary Stent Is Comparable to Bypass Surgery in Key Safety Measures in Patients with Diabetes and Multi-Vessel Disease Sep 4, 2008 |
11.5 KB |
|
|
MUNICH, Sep 04, 2008 (BUSINESS WIRE) -- Data from the largest randomized trial of its kind performed to date indicate that the use of percutaneous coronary intervention (PCI) with the CYPHER(R) Sirolimus-eluting Coronary Stent was comparable to bypass surgery (coronary artery bypass grafting or CABG) in key safety endpoints in patients with multi-v... |
|||
|
First Patient Enrolled in Study Evaluating S.M.A.R.T. (R) Nitinol Self-Expandable Stent System in Leg Disease Sep 2, 2008 |
6.8 KB |
|
|
WARREN, N.J., Sep 02, 2008 (BUSINESS WIRE) -- Cordis Corporation today announced the first patient enrollment in the STROLL trial, which will evaluate the safety and efficacy of the S.M.A.R.T. (R) Nitinol Self-Expandable Stent System in treating patients with obstructive superficial femoral artery (SFA) disease, also known as SFA atherosclerosis. T... |
|||
|
INTELENCETM (etravirine) RECEIVES MARKETING AUTHORISATION IN THE EUROPEAN UNION FOR HIV COMBINATION THERAPY Aug 29, 2008 |
11.8 KB |
|
|
CORK, IRELAND, 29th August, 2008 – The European Medicines Agency (EMEA) has granted marketing authorisation for the anti-HIV medication INTELENCETM (etravirine). INTELENCE is a next generation non-nucleoside reverse transcriptase inhibitor (NNRTI) and the first to show efficacy in patients with NNRTI-resistant HIV. INTELENCE is the first new ... |
|||
|
Ortho-McNeil Neurologics to Appeal Patent Ruling on RAZADYNE(R) Aug 28, 2008 |
8.4 KB |
|
|
TITUSVILLE, N.J., Aug 28, 2008 /PRNewswire via COMTEX News Network/ -- Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. announced that it will appeal yesterday's decision by the U.S. District Court of Delaware, which ruled the patent for RAZADYNE(R) (galantamine hydrobromide) is invalid. The decision allows FDA-a... |
|||
|
The CYPHER(R) Sirolimus-eluting Coronary Stent Outperforms the Taxus(R) Stent in People with Diabetes According to Clinical Data in the Journal of the American College of Cardiology Aug 28, 2008 |
8.5 KB |
|
|
WARREN, N.J., Aug 28, 2008 (BUSINESS WIRE) -- In patients with diabetes, the CYPHER(R) Sirolimus-eluting Coronary Stent outperformed the Taxus(R) Stent with significantly lower rates of in-segment restenosis (a reblockage within the stented area), target lesion revascularization (TLR; the need for another interventional procedure) and major adverse... |
|||
|
CYPHER SELECT(R) Plus Sirolimus-eluting Coronary Stent Receives CE Mark Approval for Treatment of Heart Attacks Aug 27, 2008 |
8.7 KB |
|
|
WARREN, N.J., Aug 27, 2008 (BUSINESS WIRE) -- Cordis Corporation today announced that it has received CE mark approval to market the CYPHER SELECT(R) Plus Sirolimus-eluting Coronary Stent for the treatment of acute myocardial infarction (AMI), more commonly known as a heart attack. CE mark approval means that the product has been deemed safe and ef... |
|||
|
FDA Issues Complete Response Letter for Paliperidone Palmitate for the Treatment of Schizophrenia Aug 26, 2008 |
7.9 KB |
|
|
TITUSVILLE, N.J., Aug 26, 2008 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that the Food and Drug Administration (FDA) has asked for additional data before it will approve the company's New Drug Application (NDA) for paliperidone palmitate, an investigational once-... |
|||
|
FDA Requires Additional Information on Doribax for Treatment of Hospital-Acquired Pneumonia Aug 21, 2008 |
11.7 KB |
|
|
Raritan, NJ August 21, 2008 — Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) today announced that the U.S. Food and Drug Administration (FDA) requires additional information before it will approve the company's New Drug Application (NDA) for DORIBAXTM (doripenem for injection) for the treatment of... |
|||
|
Ethicon Endo-Surgery To Acquire SurgRx Aug 11, 2008 |
9.4 KB |
|
|
CINCINNATI, August 11, 2008 — Ethicon Endo-Surgery announced today that it has entered into a definitive agreement to acquire SurgRx, a privately held developer of the advanced bipolar tissue sealing system used in the EnSeal family of devices. The acquisition will provide Ethicon Endo-Surgery with a new energy platform... |
|||
= add release to Briefcase
